Issue Date: December 5, 2011
Roche, PTC Research Muscular Atrophy
Roche has licensed rights to PTC Therapeutics’ drug discovery program in spinal muscular atrophy, a genetic disorder that causes muscle weakness. Roche will pay $30 million for the program, which includes three small molecules currently in preclinical development. The Swiss firm could also make up to $460 million in milestone payments. PTC developed the program in partnership with the SMA Foundation, which will remain active in the collaboration.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society